4investors 23. Juni 2021 Abivax: ABX464 mit starken Studiendaten in der Behandlung Rheumatoider Arthritis
Scrip 23. Juni 2021 AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data
PharmaTimes 26. Mai 2021 Abivax’s ABX464 shows ‘impressive’ efficacy in severe ulcerative colitis patients